Lung

Lung

Offline Online

MET exon 14 splice variants is the oncogenic driver to target

870 0 Acute Lymphoblastic Leukemia
Play
Want to watch this again later?
Sign in to add this video to a playlist. Login

Date added (newest)

Novel immune checkpoint inhibitors

Novel immune checkpoint inhibitors

CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel

CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel

MET exon 14 splice variants is the oncogenic driver to target

MET exon 14 splice variants is the oncogenic driver to target

The Future for PD pathway inhibitors in NSCLC

The Future for PD pathway inhibitors in NSCLC

AZD9291 for T790M mutant EGFR is well tolerated

AZD9291 for T790M mutant EGFR is well tolerated

TIGER X - Rociletinib for T790M EGFR mutations

TIGER X - Rociletinib for T790M EGFR mutations

How does Rociletinib differ from 1st generations EGFR TKIs?

How does Rociletinib differ from 1st generations EGFR TKIs?

ALK inhibitor Alectinib for NSCLC

ALK inhibitor Alectinib for NSCLC

LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell Carcinoma

LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell Carcinoma

Will immunotherapy combination regimens be both beneficial and safe for patients?

Will immunotherapy combination regimens be both beneficial and safe for patients?

What is the role of systemic adjuvant therapy for resected T2N0 NSCLC?

What is the role of systemic adjuvant therapy for resected T2N0 NSCLC?

What causes mechanism resistance to Rociletinib and AZD9291?

What causes mechanism resistance to Rociletinib and AZD9291?

Novel immune checkpoint inhibitors

1179 0 Acute Lymphoblastic Leukemia

RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses Novel immune checkpoint inhibitors

Want to watch this again later?
Sign in to add this video to a playlist. Login

CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel

661 0 Acute Lymphoblastic Leukemia

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University talks about the CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel

Want to watch this again later?
Sign in to add this video to a playlist. Login

MET exon 14 splice variants is the oncogenic driver to target

870 0 Acute Lymphoblastic Leukemia

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses MET exon 14 splice variants is the oncogenic driver to target

Want to watch this again later?
Sign in to add this video to a playlist. Login

The Future for PD pathway inhibitors in NSCLC

985 0 Acute Lymphoblastic Leukemia

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses the Future for PD pathway inhibitors in NSCLC

Want to watch this again later?
Sign in to add this video to a playlist. Login

AZD9291 for T790M mutant EGFR is well tolerated

704 0 Acute Lymphoblastic Leukemia

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses AZD9291 for T790M mutant EGFR is well tolerated.

Want to watch this again later?
Sign in to add this video to a playlist. Login

TIGER X - Rociletinib for T790M EGFR mutations

613 0 Acute Lymphoblastic Leukemia

LECIA SEQUIST, MD of Massachusetts General Hospital discusses TIGER X - Rociletinib for T790M EGFR mutations.

Want to watch this again later?
Sign in to add this video to a playlist. Login

How does Rociletinib differ from 1st generations EGFR TKIs?

544 0 Acute Lymphoblastic Leukemia

LECIA SEQUIST, MD of Massachusetts General Hospital answers the question How does Rociletinib differ from 1st generations EGFR TKIs?

Want to watch this again later?
Sign in to add this video to a playlist. Login

ALK inhibitor Alectinib for NSCLC

538 0 Acute Lymphoblastic Leukemia

LECIA SEQUIST, MD of Massachusetts General Hospital discusses ALK inhibitor Alectinib for NSCLC

Want to watch this again later?
Sign in to add this video to a playlist. Login

LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell Carcinoma

328 0 Acute Lymphoblastic Leukemia

LECIA SEQUIST, MD of Massachusetts General Hospital discusses LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell Carcinoma.

Want to watch this again later?
Sign in to add this video to a playlist. Login

Will immunotherapy combination regimens be both beneficial and safe for patients?

490 0 Acute Lymphoblastic Leukemia

RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine answers the question Will immunotherapy combination regimens be both beneficial and safe for patients?

Want to watch this again later?
Sign in to add this video to a playlist. Login

What is the role of systemic adjuvant therapy for resected T2N0 NSCLC?

484 0 Acute Lymphoblastic Leukemia

RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses the role of systemic adjuvant therapy for resected T2N0 NSCLC

Want to watch this again later?
Sign in to add this video to a playlist. Login

What causes mechanism resistance to Rociletinib and AZD9291?

354 0 Acute Lymphoblastic Leukemia

DAVID ROSS CAMIDGE, MD, PHD discusses what causes mechanism resistance to Rociletinib and AZD929

Want to watch this again later?
Sign in to add this video to a playlist. Login
My videos
Novel immune checkpoint inhibitors

Novel immune checkpoint inhibitors
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses Novel immune checkpoint inhibitors
1,179 Views
7 years Ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel
CheckMate 057 trial in non-squamous and the CheckMate 017...
661 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
MET exon 14 splice variants is the oncogenic driver to target
MET exon 14 splice variants is the oncogenic driver to ta...
870 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Future for PD pathway inhibitors in NSCLC
The Future for PD pathway inhibitors in NSCLC
985 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
AZD9291 for T790M mutant EGFR is well tolerated
AZD9291 for T790M mutant EGFR is well tolerated
704 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
TIGER X - Rociletinib for T790M EGFR mutations
TIGER X - Rociletinib for T790M EGFR mutations
613 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
How does Rociletinib differ from 1st generations EGFR TKIs?
How does Rociletinib differ from 1st generations EGFR TKIs?
544 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
ALK inhibitor Alectinib for NSCLC
ALK inhibitor Alectinib for NSCLC
538 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell Carcinoma
LUX-Lung 8 trial and the role of EGFR inhibitors in Squam...
328 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
Will immunotherapy combination regimens be both beneficial and safe for patients?
Will immunotherapy combination regimens be both beneficia...
490 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
What is the role of systemic adjuvant therapy for resected T2N0 NSCLC?
What is the role of systemic adjuvant therapy for resect...
484 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
What causes mechanism resistance to Rociletinib and AZD9291?
What causes mechanism resistance to Rociletinib and AZD9291?
354 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
What is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?
What is the future for PD pathway inhibitors in combinati...
392 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
Novel investigational agents for crizotinib resistant ALK-positive NSCLC.
Novel investigational agents for crizotinib resistant ALK...
518 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
The role of T790M mutations in resistance to first generation EGFR TKIs and what role agents such as Rociletinib may have in the future.
The role of T790M mutations in resistance to first genera...
499 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
The role of MET in NSCLC and why earlier TKIs and antibodies have been disappointing.
The role of MET in NSCLC and why earlier TKIs and antibod...
207 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase II study of cabozantinib in RET rearranged NSCLC
Phase II study of cabozantinib in RET rearranged NSCLC
445 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
The role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.
The role of BRAF mutations in NSCLC and the potential tre...
555 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Lung Cancer Mutation Consortium and the role of Next Generation Sequencing in NSCLC.
The Lung Cancer Mutation Consortium and the role of Next ...
833 Views
7 years Ago
Lung
Want to watch this again later?
Sign in to add this video to a playlist. Login
Loading